免疫球蛋白有艾滋?药监局公布调查结果…

2019-02-20 徐钰琦 环球医学

日前,江西省疾控中心检测到上海某医药股份有限公司静注人免疫球蛋白(批号:20180610z)出现艾滋病抗体阳性事件引发大家广泛关注。随后,国家卫健委作出回应,要求立即开展药品排摸和封存工作,尽快查清事实,切实加强药品管理,确保群众用药安全。事情进展如何了?2月5日,国家卫健委接到上海某医药控股有限公司静注人免疫球蛋白艾滋病抗体阳性有关情况的报告后,立即通报国家药监局,并要求全国各医疗机构暂停使用和

日前,江西省疾控中心检测到上海某医药股份有限公司静注人免疫球蛋白(批号:20180610z)出现艾滋病抗体阳性事件引发大家广泛关注。随后,国家卫健委作出回应,要求立即开展药品排摸和封存工作,尽快查清事实,切实加强药品管理,确保群众用药安全。事情进展如何了?

2月5日,国家卫健委接到上海某医药控股有限公司静注人免疫球蛋白艾滋病抗体阳性有关情况的报告后,立即通报国家药监局,并要求全国各医疗机构暂停使用和封存该公司问题批次药品,做好相关患者的病情观察和监测,配合药品监管部门作好情况调查和药品处置工作;并第一时间派出工作组赴地方指导工作,并召集专家对有关问题进行分析研判。

国家药监局接到国家卫健委通报后,立即要求上海市药监局对该企业展开现场检查,组织对同批原料血浆生产的产品和相邻批次产品进行检验,控制企业所有相关生产和检验记录,对产品抽样送检;并要求企业停产,启动紧急召回。各省市卫健委相继通知全市医疗机构暂停使用相关产品。

国家卫健委表示,根据国际相关文献报道,结合该药品灭活病毒的生产工艺特点和产品PH值等因素,专家认为使用该药品的患者感染艾滋病的风险很低。国家卫健委已组织制定了使用该药品患者的随访监测方案,本着对人民高度负责的精神,指导地方做好相关患者随访观察,配合国家药监局共同做好后续处置工作。

事情发生将近半个月,情况如何了?近日,上海方面对某股份有限公司生产的涉事批次静注人免疫球蛋白进行了艾滋病、乙肝、丙肝三种病毒核酸检测,结果均为阴性;江西方面对患者的艾滋病病毒核酸检测,结果也为阴性。

用彻查回应舆论关切,用依法处置直面公众疑虑。保障药品安全关乎道德,更关乎法律,是民生工程,也是民心工程。人命关天,天大之事,确保每一种药、每一粒药万无一失。对人民负责,制药企业须存敬畏,监管部门严防严管严控,不让任何一道防线被洞穿。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2035188, encodeId=00152035188e3, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Mon Sep 02 03:04:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361355, encodeId=1a71361355eb, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sat Feb 23 20:36:15 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283899, encodeId=586d12838994a, content=<a href='/topic/show?id=ce1b2908938' target=_blank style='color:#2F92EE;'>#免疫球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29089, encryptionId=ce1b2908938, topicName=免疫球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Fri Feb 22 06:04:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301647, encodeId=f25a130164ecd, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Fri Feb 22 06:04:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537888, encodeId=f598153e888ad, content=<a href='/topic/show?id=e3a39203226' target=_blank style='color:#2F92EE;'>#调查结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92032, encryptionId=e3a39203226, topicName=调查结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=904e12916305, createdName=zll0629, createdTime=Fri Feb 22 06:04:00 CST 2019, time=2019-02-22, status=1, ipAttribution=)]
    2019-09-02 xzw113
  2. [GetPortalCommentsPageByObjectIdResponse(id=2035188, encodeId=00152035188e3, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Mon Sep 02 03:04:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361355, encodeId=1a71361355eb, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sat Feb 23 20:36:15 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283899, encodeId=586d12838994a, content=<a href='/topic/show?id=ce1b2908938' target=_blank style='color:#2F92EE;'>#免疫球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29089, encryptionId=ce1b2908938, topicName=免疫球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Fri Feb 22 06:04:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301647, encodeId=f25a130164ecd, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Fri Feb 22 06:04:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537888, encodeId=f598153e888ad, content=<a href='/topic/show?id=e3a39203226' target=_blank style='color:#2F92EE;'>#调查结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92032, encryptionId=e3a39203226, topicName=调查结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=904e12916305, createdName=zll0629, createdTime=Fri Feb 22 06:04:00 CST 2019, time=2019-02-22, status=1, ipAttribution=)]
    2019-02-23 清风拂面

    谢谢分享学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2035188, encodeId=00152035188e3, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Mon Sep 02 03:04:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361355, encodeId=1a71361355eb, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sat Feb 23 20:36:15 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283899, encodeId=586d12838994a, content=<a href='/topic/show?id=ce1b2908938' target=_blank style='color:#2F92EE;'>#免疫球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29089, encryptionId=ce1b2908938, topicName=免疫球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Fri Feb 22 06:04:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301647, encodeId=f25a130164ecd, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Fri Feb 22 06:04:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537888, encodeId=f598153e888ad, content=<a href='/topic/show?id=e3a39203226' target=_blank style='color:#2F92EE;'>#调查结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92032, encryptionId=e3a39203226, topicName=调查结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=904e12916305, createdName=zll0629, createdTime=Fri Feb 22 06:04:00 CST 2019, time=2019-02-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2035188, encodeId=00152035188e3, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Mon Sep 02 03:04:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361355, encodeId=1a71361355eb, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sat Feb 23 20:36:15 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283899, encodeId=586d12838994a, content=<a href='/topic/show?id=ce1b2908938' target=_blank style='color:#2F92EE;'>#免疫球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29089, encryptionId=ce1b2908938, topicName=免疫球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Fri Feb 22 06:04:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301647, encodeId=f25a130164ecd, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Fri Feb 22 06:04:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537888, encodeId=f598153e888ad, content=<a href='/topic/show?id=e3a39203226' target=_blank style='color:#2F92EE;'>#调查结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92032, encryptionId=e3a39203226, topicName=调查结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=904e12916305, createdName=zll0629, createdTime=Fri Feb 22 06:04:00 CST 2019, time=2019-02-22, status=1, ipAttribution=)]
    2019-02-22 xuyu
  5. [GetPortalCommentsPageByObjectIdResponse(id=2035188, encodeId=00152035188e3, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Mon Sep 02 03:04:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361355, encodeId=1a71361355eb, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sat Feb 23 20:36:15 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283899, encodeId=586d12838994a, content=<a href='/topic/show?id=ce1b2908938' target=_blank style='color:#2F92EE;'>#免疫球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29089, encryptionId=ce1b2908938, topicName=免疫球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Fri Feb 22 06:04:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301647, encodeId=f25a130164ecd, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Fri Feb 22 06:04:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537888, encodeId=f598153e888ad, content=<a href='/topic/show?id=e3a39203226' target=_blank style='color:#2F92EE;'>#调查结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92032, encryptionId=e3a39203226, topicName=调查结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=904e12916305, createdName=zll0629, createdTime=Fri Feb 22 06:04:00 CST 2019, time=2019-02-22, status=1, ipAttribution=)]

相关资讯

Turk Arch Otorhinolaryngol:在选择性免疫球蛋白A缺陷病人中的感官听力损失研究

最近,有研究人员评估了在患有选择习惯免疫球蛋白A(lgA)缺陷(SIGAD)的儿科病人中评估了听力的功能。研究人员在28名患有SIGAD的非传染时期的的患者中进行了纯音听力测定、声波阻抗、耳声发射和脑干听力测定,并在28名健康儿童且具有正常耳镜检查的同样进行了上述检查。最后,研究人员对2个小组的听力损失检查结果进行了比较。研究发现,在SIGAD小组中,2个男性患者的1个女性患者被发现具有感官听力损

Lancet Neurol:芬戈莫德不能延缓慢性炎性脱髓鞘性多神经根神经病进展

研究认为,0.5mg芬戈莫德治疗对延缓慢性炎性脱髓鞘性多神经根神经病进展的效果不显著

Am J Rhinol Allergy:利用鼻腔细胞学和免疫球蛋白E抗体水平对过敏性鼻炎症候的评估

在婴幼儿中鉴定过敏性鼻炎的症候是困难的,因为做出一个总结性的诊断具有挑战。研究人员利用鼻拭子中细胞的差异和对食物和吸入性过敏原的免疫球蛋白E(slgE)抗体水平值来进行诊断,并且鉴定了相关的过敏原来对过敏性鼻炎的症候进行了调查。研究包括了302名儿童,年龄在2到120个月,并且他们都因流鼻涕而在他们的诊所治疗。研究发现,参与者在2-14个月(n=84)、15-24个月(n=57)、 25-60 个

Blood:CCND2和CCND3可通过劫持免疫球蛋白轻链增强子上调细胞周期蛋白的表达

中心点:在细胞周期蛋白D1-套细胞淋巴瘤中,IG轻链增强子的隐式插入与CCND2和CCND3过表达相关。大部分细胞周期蛋白D1-套细胞淋巴瘤携带CCND2或CCND3重排,而小部分表现为CCNE1和CCNE2上调。摘要:套细胞淋巴瘤(MCL)的特征是他(11;14)(q13;q32)易位,导致细胞周期蛋白D1过表达。但是,现在发现一个细胞周期蛋白D1阴性的MCL(CCND1-MCL)小子集,其大约

国家药监局公布涉事批次静注人免疫球蛋白检测结果:阴性

记者7日从国家药监局获悉,上海方面对上海新兴医药股份有限公司生产的涉事批次静注人免疫球蛋白进行的艾滋病、乙肝、丙肝三种病毒核酸检测,结果均为阴性;江西方面对患者的艾滋病病毒核酸检测,结果为阴性。  国家药监局5日接到国家卫生健康委通报,上海新兴医药股份有限公司生产的一批次静注人免疫球蛋白(批号:20180610Z)艾滋病病毒抗体检测为阳性。国家药监局立即要求上海市药监局对上海新兴开展现场检查,组织

Blood:ITP患儿确诊时予以IVIg预治疗可提高早期缓解率,但不影响慢性ITP发生率

中心点:对于新确诊的ITP患儿,确诊时予以IVIg治疗并不能降低慢性ITP的发生率。用IVIg进行预治疗有助于快速恢复、减少重度出血事件。摘要:对于新确诊的免疫性血小板减少症(ITP)患儿可予以密切观察或免疫调节治疗。观察性研究提示静脉输注免疫球蛋白(IVIg)治疗可降低患儿慢性ITP的发生率。Katja M.J. Heitink-Pollé等人开展一多中心的随机试验,招募3个月-16岁的新确诊的